Biotech Values

[p3analyze]

Understood. Either OS becomes a focal point, or it doesn't.
That's what I was saying, it's too conservative to think that 74% probability of OS becoming the focal point because this is an accelerated approval application.

In addition, I think assigning a 35% probability to 2b,ie panel thinks existing data package eg PFS plus pain as not compelling, is also too conservative. The radiological progression sensitivity analysis, the pain endpoint, plus the trending positive OS data, aren't they compelling enough?